According to manufacturer Roche, the decision to discontinue Viracept was based on several factors, including decreasing demand and exclusion of the drug from most clinical guidelines. In addition, alternative treatment options with improved risk-benefit profiles are now available.
Viracept is indicated in antiretroviral combination treatment of HIV infection in adults, adolescents and children aged three years and over.
Clinicians are advised not to start any new patients on Viracept and to discuss alternative treatment options with those patients currently receiving the drug.
Further information: Roche